In a statement, Karoline Leavitt said the person who fainted was a representative of one of the pharmaceutical companies, adding that the White House Medical Unit quickly jumped into action, and the gentleman is okay. In a statement to ABC News, Novo Nordisk said the person who fainted was not one of their executives
It's advisable to keep it in its original container, out of reach of children and pets
The first three months after your final dose are when weight regain risk is highest
Nature 610 , 562568 (2022)
Growth hormone levels typically decline with age, which can affect energy levels, recovery time, and body composition
Key evidence points: GLP-1 medications do not directly target or break down muscle tissue Lean mass loss occurs as a consequence of the calorie deficit and weight reduction The proportion of lean mass lost is comparable to other weight loss methods Greater absolute lean mass loss reflects the greater total weight loss achieved Regulatory bodies including NICE and the MHRA have not identified muscle loss as a specific adverse effect requiring special warnings in the Summary of Product Characteristics (SmPCs), though healthcare professionals are advised to monitor nutritional status and encourage appropriate dietary protein intake and physical activity in patients using these medications for weight management
